Predicting Outcome in Guillain-Barré Syndrome

In the Research Article “Predicting Outcome in Guillain-Barré Syndrome: International Validation of the Modified Erasmus GBS Outcome Score” by Doets et al.,¹ the X-axis of Figure 3B should range from 0 to 12 points. The corrected figure follows. The editorial staff regret the error.

Figure 3. Predicted Proportion of Patients Unable to Walk Independently Based on Original and Recalibrated mEGOS.

Predicted probabilities of not being able to walk independently at 4 weeks and 6 months based on the modified Erasmus GBS Outcome Score (mEGOS) at entry (A) and mEGOS at week 1 (B). Probability graphs are based on the original mEGOS model (red) and the recalibrated model for the Europe/North America subgroup (green). Dashed and gray areas around the curves represent the 95% confidence intervals. The top (red and green) graphs provide the probabilities of not being able to walk independently at 4 weeks, and the bottom (red and green) graphs provide probabilities at 6 months. The mEGOS model can be used in all patients with Guillain-Barré syndrome (GBS) and variants of GBS who have lost the ability to walk. The mEGOS score can be calculated based on the scoring system provided in Table 1. Based on the mEGOS score and Figure 3, the probability of being unable to walk independently at 4 weeks or 6 months can be deduced for an individual patient. For predictions with the mEGOS in European and North American patients with GBS, the probability of poor outcome can be determined using the probability graphs based on the recalibrated model (green lines). For predictions in patients with GBS from countries outside Europe and North America, the probability graphs based on the original mEGOS model can be used (red lines).